 CHICAGO--BUSINESS WIRE--Xeris Pharmaceuticals, Inc. Nasdaq: XERS, a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that on July 1, 2021, the Compensation Committee of Xeris Board of Directors granted restricted stock units for an aggregate of 80,250 shares of its common stock to 37 new employees under Xeris Inducement Equity Plan. Xeris Inducement Equity Plan is used excl 